WO2008027558A2
(en)
|
2006-08-31 |
2008-03-06 |
Codon Devices, Inc. |
Iterative nucleic acid assembly using activation of vector-encoded traits
|
US10457935B2
(en)
|
2010-11-12 |
2019-10-29 |
Gen9, Inc. |
Protein arrays and methods of using and making the same
|
EP3360963B1
(en)
|
2010-11-12 |
2019-11-06 |
Gen9, Inc. |
Methods and devices for nucleic acids synthesis
|
US11560585B2
(en)
|
2011-01-31 |
2023-01-24 |
Roche Sequencing Solutions, Inc. |
Methods of identifying multiple epitopes in cells
|
EP2670863B1
(en)
|
2011-01-31 |
2018-06-27 |
H. Hoffnabb-La Roche Ag |
Methods of identifying multiple epitopes in cells
|
WO2013066438A2
(en)
|
2011-07-22 |
2013-05-10 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
LT3594340T
(lt)
|
2011-08-26 |
2021-10-25 |
Gen9, Inc. |
Kompozicijos ir būdai, skirti nukleorūgščių didelio tikslumo sąrankai
|
US11021737B2
(en)
|
2011-12-22 |
2021-06-01 |
President And Fellows Of Harvard College |
Compositions and methods for analyte detection
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
US9637739B2
(en)
|
2012-03-20 |
2017-05-02 |
Vilnius University |
RNA-directed DNA cleavage by the Cas9-crRNA complex
|
US9150853B2
(en)
|
2012-03-21 |
2015-10-06 |
Gen9, Inc. |
Methods for screening proteins using DNA encoded chemical libraries as templates for enzyme catalysis
|
CN111876409A
(zh)
|
2012-04-24 |
2020-11-03 |
Gen9股份有限公司 |
在体外克隆中分选核酸和多重制备物的方法
|
MX362523B
(es)
|
2012-04-25 |
2019-01-22 |
Regeneron Pharma |
Direccion transmitida por nucleasa con vectores de direccion grandes.
|
DK3401400T3
(da)
|
2012-05-25 |
2019-06-03 |
Univ California |
Fremgangsmåder og sammensætninger til rna-styret mål-dna-modifikation og til rna-styret transskriptionsmodulering
|
CA2877290A1
(en)
|
2012-06-19 |
2013-12-27 |
Daniel F. Voytas |
Gene targeting in plants using dna viruses
|
CA2877823A1
(en)
|
2012-06-25 |
2014-01-03 |
Gen9, Inc. |
Methods for nucleic acid assembly and high throughput sequencing
|
CN116064532A
(zh)
|
2012-10-23 |
2023-05-05 |
基因工具股份有限公司 |
用于切割靶dna的组合物及其用途
|
KR101844123B1
(ko)
*
|
2012-12-06 |
2018-04-02 |
시그마-알드리치 컴퍼니., 엘엘씨 |
Crispr-기초된 유전체 변형과 조절
|
US20140242664A1
(en)
|
2012-12-12 |
2014-08-28 |
The Broad Institute, Inc. |
Engineering of systems, methods and optimized guide compositions for sequence manipulation
|
ES2883590T3
(es)
|
2012-12-12 |
2021-12-09 |
Broad Inst Inc |
Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas
|
WO2014093595A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Crispr-cas component systems, methods and compositions for sequence manipulation
|
EP3064585B1
(en)
*
|
2012-12-12 |
2020-02-05 |
The Broad Institute, Inc. |
Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
|
ES2701749T3
(es)
|
2012-12-12 |
2019-02-25 |
Broad Inst Inc |
Métodos, modelos, sistemas y aparatos para identificar secuencias diana para enzimas Cas o sistemas CRISPR-Cas para secuencias diana y transmitir resultados de los mismos
|
US20140310830A1
(en)
|
2012-12-12 |
2014-10-16 |
Feng Zhang |
CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
KR20150105634A
(ko)
|
2012-12-12 |
2015-09-17 |
더 브로드 인스티튜트, 인코퍼레이티드 |
서열 조작을 위한 개선된 시스템, 방법 및 효소 조성물의 유전자 조작 및 최적화
|
DK2931898T3
(en)
|
2012-12-12 |
2016-06-20 |
Massachusetts Inst Technology |
CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
|
ES2741951T3
(es)
|
2012-12-17 |
2020-02-12 |
Harvard College |
Modificación por ingeniería genética del genoma humano guiada por ARN
|
WO2014113493A1
(en)
|
2013-01-16 |
2014-07-24 |
Emory University |
Cas9-nucleic acid complexes and uses related thereto
|
WO2014130706A1
(en)
|
2013-02-20 |
2014-08-28 |
Regeneron Pharmaceuticals, Inc. |
Genetic modification of rats
|
EP3578666A1
(en)
|
2013-03-12 |
2019-12-11 |
President and Fellows of Harvard College |
Method of generating a three-dimensional nucleic acid containing matrix
|
RU2018122288A
(ru)
|
2013-03-14 |
2019-03-06 |
Карибо Биосайенсиз, Инк. |
Композиции и способы с участием нуклеиновых кислот, нацеленных на нуклеиновые кислоты
|
US9234213B2
(en)
|
2013-03-15 |
2016-01-12 |
System Biosciences, Llc |
Compositions and methods directed to CRISPR/Cas genomic engineering systems
|
US20140273230A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Sigma-Aldrich Co., Llc |
Crispr-based genome modification and regulation
|
MX2015011985A
(es)
*
|
2013-03-15 |
2016-04-07 |
Univ Minnesota |
Ingenieria genomica de plantas utilizando sistemas crispr/cas.
|
EP2970986B1
(en)
*
|
2013-03-15 |
2020-05-06 |
The General Hospital Corporation |
Rna-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
US10760064B2
(en)
|
2013-03-15 |
2020-09-01 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
CN115261411A
(zh)
|
2013-04-04 |
2022-11-01 |
哈佛学院校长同事会 |
利用CRISPR/Cas系统的基因组编辑的治疗性用途
|
KR20200136508A
(ko)
|
2013-04-16 |
2020-12-07 |
리제너론 파마슈티칼스 인코포레이티드 |
랫트 게놈의 표적화된 변형
|
EP2997146A4
(en)
|
2013-05-15 |
2017-04-26 |
Sangamo BioSciences, Inc. |
Methods and compositions for treatment of a genetic condition
|
US9873907B2
(en)
|
2013-05-29 |
2018-01-23 |
Agilent Technologies, Inc. |
Method for fragmenting genomic DNA using CAS9
|
SG10201710030QA
(en)
*
|
2013-06-04 |
2018-01-30 |
Harvard College |
Rna-guided transcriptional regulation
|
US20140356956A1
(en)
*
|
2013-06-04 |
2014-12-04 |
President And Fellows Of Harvard College |
RNA-Guided Transcriptional Regulation
|
AU2014281027A1
(en)
|
2013-06-17 |
2016-01-28 |
Massachusetts Institute Of Technology |
Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation
|
RU2716421C2
(ru)
|
2013-06-17 |
2020-03-11 |
Те Брод Инститьют Инк. |
Доставка, применение и применения в терапии систем crispr-cas и композиций для целенаправленного воздействия на нарушения и заболевания с использованием вирусных компонентов
|
EP3674411A1
(en)
|
2013-06-17 |
2020-07-01 |
The Broad Institute, Inc. |
Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
|
EP3011033B1
(en)
|
2013-06-17 |
2020-02-19 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
CA2915842C
(en)
|
2013-06-17 |
2022-11-29 |
The Broad Institute, Inc. |
Delivery and use of the crispr-cas systems, vectors and compositions for hepatic targeting and therapy
|
US10011850B2
(en)
|
2013-06-21 |
2018-07-03 |
The General Hospital Corporation |
Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
|
JP2016528890A
(ja)
|
2013-07-09 |
2016-09-23 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
CRISPR/Cas系を用いるゲノム編集の治療用の使用
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
US20150044772A1
(en)
*
|
2013-08-09 |
2015-02-12 |
Sage Labs, Inc. |
Crispr/cas system-based novel fusion protein and its applications in genome editing
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
CA2922090C
(en)
|
2013-08-22 |
2021-05-18 |
Pioneer Hi-Bred International, Inc. |
Genome modification using guide polynucleotide/cas endonuclease systems and methods of use
|
WO2015031775A1
(en)
|
2013-08-29 |
2015-03-05 |
Temple University Of The Commonwealth System Of Higher Education |
Methods and compositions for rna-guided treatment of hiv infection
|
US9388430B2
(en)
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
US9340800B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
Extended DNA-sensing GRNAS
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
EP3988649A1
(en)
|
2013-09-18 |
2022-04-27 |
Kymab Limited |
Methods, cells and organisms
|
US9957526B2
(en)
*
|
2013-10-17 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
WO2015065964A1
(en)
|
2013-10-28 |
2015-05-07 |
The Broad Institute Inc. |
Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
|
US10584358B2
(en)
|
2013-10-30 |
2020-03-10 |
North Carolina State University |
Compositions and methods related to a type-II CRISPR-Cas system in Lactobacillus buchneri
|
WO2015070083A1
(en)
|
2013-11-07 |
2015-05-14 |
Editas Medicine,Inc. |
CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS
|
US10787684B2
(en)
*
|
2013-11-19 |
2020-09-29 |
President And Fellows Of Harvard College |
Large gene excision and insertion
|
CA2933433C
(en)
|
2013-12-11 |
2020-11-17 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for the targeted modification of a genome
|
HUE041331T2
(hu)
|
2013-12-11 |
2019-05-28 |
Regeneron Pharma |
Módszerek és készítmények a genom célzott módosításához
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
CA2932439A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute, Inc. |
Crispr-cas systems and methods for altering expression of gene products, structural information and inducible modular cas enzymes
|
WO2015089486A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
SG10201804976YA
(en)
|
2013-12-12 |
2018-07-30 |
Broad Inst Inc |
Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for Genome Editing
|
WO2015089351A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
|
US20150165054A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
US10787654B2
(en)
|
2014-01-24 |
2020-09-29 |
North Carolina State University |
Methods and compositions for sequence guiding Cas9 targeting
|
EP3105328B1
(en)
|
2014-02-11 |
2020-04-08 |
The Regents of the University of Colorado, a body corporate |
Crispr enabled multiplexed genome engineering
|
EP3957735A1
(en)
|
2014-03-05 |
2022-02-23 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
|
US11141493B2
(en)
|
2014-03-10 |
2021-10-12 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
DK3116997T3
(da)
|
2014-03-10 |
2019-08-19 |
Editas Medicine Inc |
Crispr/cas-relaterede fremgangsmåder og sammensætninger til behandling af lebers kongenitale amaurose 10 (lca10)
|
US11339437B2
(en)
|
2014-03-10 |
2022-05-24 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
EP3981876A1
(en)
|
2014-03-26 |
2022-04-13 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating sickle cell disease
|
JP2017512481A
(ja)
|
2014-04-08 |
2017-05-25 |
ノースカロライナ ステート ユニバーシティーNorth Carolina State University |
Crispr関連遺伝子を用いた、rna依存性の転写抑制のための方法および組成物
|
SG11201610028TA
(en)
|
2014-05-30 |
2016-12-29 |
Univ Leland Stanford Junior |
Compositions and methods of delivering treatments for latent viral infections
|
WO2015188109A1
(en)
|
2014-06-06 |
2015-12-10 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for modifying a targeted locus
|
RU2707911C2
(ru)
|
2014-06-23 |
2019-12-02 |
Регенерон Фармасьютикалз, Инк. |
Опосредованная нуклеазой сборка днк
|
WO2015200805A2
(en)
|
2014-06-26 |
2015-12-30 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for targeted genetic modifications and methods of use
|
EP3166391A1
(en)
|
2014-07-11 |
2017-05-17 |
E. I. du Pont de Nemours and Company |
Compositions and methods for producing plants resistant to glyphosate herbicide
|
US11254933B2
(en)
|
2014-07-14 |
2022-02-22 |
The Regents Of The University Of California |
CRISPR/Cas transcriptional modulation
|
AU2015298571B2
(en)
|
2014-07-30 |
2020-09-03 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
AU2015305570C1
(en)
|
2014-08-19 |
2020-07-23 |
President And Fellows Of Harvard College |
RNA-guided systems for probing and mapping of nucleic acids
|
EP3186376B1
(en)
*
|
2014-08-27 |
2019-03-20 |
Caribou Biosciences, Inc. |
Methods for increasing cas9-mediated engineering efficiency
|
WO2016033298A1
(en)
|
2014-08-28 |
2016-03-03 |
North Carolina State University |
Novel cas9 proteins and guiding features for dna targeting and genome editing
|
US10570418B2
(en)
|
2014-09-02 |
2020-02-25 |
The Regents Of The University Of California |
Methods and compositions for RNA-directed target DNA modification
|
WO2016040594A1
(en)
*
|
2014-09-10 |
2016-03-17 |
The Regents Of The University Of California |
Reconstruction of ancestral cells by enzymatic recording
|
MX2017002930A
(es)
|
2014-09-12 |
2017-06-06 |
Du Pont |
Generacion de sitios de integracion especifica de sitio para loci de rasgos complejos en maiz y soja, y metodos de uso.
|
EP3998344A1
(en)
*
|
2014-10-09 |
2022-05-18 |
Life Technologies Corporation |
Crispr oligonucleotides and gene editing
|
EP3207124B1
(en)
|
2014-10-15 |
2019-06-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for generating or maintaining pluripotent cells
|
US20170306306A1
(en)
*
|
2014-10-24 |
2017-10-26 |
Life Technologies Corporation |
Compositions and Methods for Enhancing Homologous Recombination
|
CN107206015A
(zh)
|
2014-10-24 |
2017-09-26 |
阿维塔斯有限公司 |
透细胞质膜的传递
|
CA2963820A1
(en)
|
2014-11-07 |
2016-05-12 |
Editas Medicine, Inc. |
Methods for improving crispr/cas-mediated genome-editing
|
CA3176380A1
(en)
|
2014-11-21 |
2016-05-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for targeted genetic modification using paired guide rnas
|
CN105695485B
(zh)
*
|
2014-11-27 |
2020-02-21 |
中国科学院上海生命科学研究院 |
一种用于丝状真菌Crispr-Cas系统的Cas9编码基因及其应用
|
GB201421096D0
(en)
|
2014-11-27 |
2015-01-14 |
Imp Innovations Ltd |
Genome editing methods
|
WO2016089433A1
(en)
|
2014-12-03 |
2016-06-09 |
Agilent Technologies, Inc. |
Guide rna with chemical modifications
|
US9888673B2
(en)
|
2014-12-10 |
2018-02-13 |
Regents Of The University Of Minnesota |
Genetically modified cells, tissues, and organs for treating disease
|
EP3889260A1
(en)
|
2014-12-12 |
2021-10-06 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
US11326184B2
(en)
|
2014-12-19 |
2022-05-10 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for targeted genetic modification through single-step multiple targeting
|
WO2016100857A1
(en)
|
2014-12-19 |
2016-06-23 |
Regeneron Pharmaceuticals, Inc. |
Stem cells for modeling type 2 diabetes
|
US20180320241A1
(en)
*
|
2014-12-19 |
2018-11-08 |
Roche Sequencing Solutions, Inc. |
Methods for identifying multiple epitopes in selected sub-populations of cells
|
EP3245232B1
(en)
|
2015-01-12 |
2021-04-21 |
The Regents of The University of California |
Heterodimeric cas9 and methods of use thereof
|
EP3250689B1
(en)
|
2015-01-28 |
2020-11-04 |
The Regents of The University of California |
Methods and compositions for labeling a single-stranded target nucleic acid
|
EP3798302A1
(fr)
*
|
2015-01-29 |
2021-03-31 |
Meiogenix |
Procede pour induire des recombinaisons meiotiques ciblees
|
WO2016149422A1
(en)
*
|
2015-03-16 |
2016-09-22 |
The Broad Institute, Inc. |
Encoding of dna vector identity via iterative hybridization detection of a barcode transcript
|
BR112017017260A2
(pt)
|
2015-03-27 |
2018-04-17 |
Du Pont |
construções de dna, vetor, célula, plantas, semente, método de expressão de rna e método de modificação de local alvo
|
KR20240038141A
(ko)
|
2015-04-06 |
2024-03-22 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna
|
US11180793B2
(en)
|
2015-04-24 |
2021-11-23 |
Editas Medicine, Inc. |
Evaluation of Cas9 molecule/guide RNA molecule complexes
|
WO2016182959A1
(en)
|
2015-05-11 |
2016-11-17 |
Editas Medicine, Inc. |
Optimized crispr/cas9 systems and methods for gene editing in stem cells
|
WO2016183448A1
(en)
*
|
2015-05-14 |
2016-11-17 |
University Of Southern California |
Optimized gene editing utilizing a recombinant endonuclease system
|
GB2543873A
(en)
|
2015-05-29 |
2017-05-03 |
Agenovir Corp |
Compositions and methods for cell targeted HPV treatment
|
EA201792663A1
(ru)
|
2015-05-29 |
2018-04-30 |
Норт Каролина Стейт Юниверсити |
Способы скрининга бактерий, архей, водорослей и дрожжей с использованием нуклеиновых кислот crispr
|
US10117911B2
(en)
|
2015-05-29 |
2018-11-06 |
Agenovir Corporation |
Compositions and methods to treat herpes simplex virus infections
|
EP3303634B1
(en)
|
2015-06-03 |
2023-08-30 |
The Regents of The University of California |
Cas9 variants and methods of use thereof
|
US20180296537A1
(en)
|
2015-06-05 |
2018-10-18 |
Novartis Ag |
Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
|
US11911415B2
(en)
|
2015-06-09 |
2024-02-27 |
Editas Medicine, Inc. |
CRISPR/Cas-related methods and compositions for improving transplantation
|
KR20220158846A
(ko)
|
2015-06-15 |
2022-12-01 |
노쓰 캐롤라이나 스테이트 유니버시티 |
핵산 및 rna-기반 항미생물제를 효율적으로 전달하기 위한 방법 및 조성물
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
AU2016279062A1
(en)
|
2015-06-18 |
2019-03-28 |
Omar O. Abudayyeh |
Novel CRISPR enzymes and systems
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
CN109536474A
(zh)
|
2015-06-18 |
2019-03-29 |
布罗德研究所有限公司 |
降低脱靶效应的crispr酶突变
|
WO2017004261A1
(en)
|
2015-06-29 |
2017-01-05 |
Ionis Pharmaceuticals, Inc. |
Modified crispr rna and modified single crispr rna and uses thereof
|
US11479793B2
(en)
|
2015-07-15 |
2022-10-25 |
Rutgers, The State University Of New Jersey |
Nuclease-independent targeted gene editing platform and uses thereof
|
WO2017023801A1
(en)
|
2015-07-31 |
2017-02-09 |
Regents Of The University Of Minnesota |
Intracellular genomic transplant and methods of therapy
|
CA2995036A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Tunable endogenous protein degradation
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
US9926546B2
(en)
|
2015-08-28 |
2018-03-27 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
CN108350449B
(zh)
|
2015-08-28 |
2022-05-31 |
通用医疗公司 |
工程化的CRISPR-Cas9核酸酶
|
WO2017040511A1
(en)
|
2015-08-31 |
2017-03-09 |
Agilent Technologies, Inc. |
Compounds and methods for crispr/cas-based genome editing by homologous recombination
|
WO2017040786A1
(en)
*
|
2015-09-04 |
2017-03-09 |
Massachusetts Institute Of Technology |
Multilayer genetic safety kill circuits based on single cas9 protein and multiple engineered grna in mammalian cells
|
WO2017049129A2
(en)
*
|
2015-09-18 |
2017-03-23 |
President And Fellows Of Harvard College |
Methods of making guide rna
|
US20180237800A1
(en)
*
|
2015-09-21 |
2018-08-23 |
The Regents Of The University Of California |
Compositions and methods for target nucleic acid modification
|
EP3786294A1
(en)
|
2015-09-24 |
2021-03-03 |
Editas Medicine, Inc. |
Use of exonucleases to improve crispr/cas-mediated genome editing
|
US11286480B2
(en)
|
2015-09-28 |
2022-03-29 |
North Carolina State University |
Methods and compositions for sequence specific antimicrobials
|
WO2017062723A1
(en)
*
|
2015-10-08 |
2017-04-13 |
President And Fellows Of Harvard College |
Multiplexed genome editing
|
JP7109784B2
(ja)
|
2015-10-23 |
2022-08-01 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
遺伝子編集のための進化したCas9蛋白質
|
US11111508B2
(en)
|
2015-10-30 |
2021-09-07 |
Brandeis University |
Modified CAS9 compositions and methods of use
|
EP3371329A4
(en)
|
2015-11-03 |
2019-06-19 |
President and Fellows of Harvard College |
METHOD AND DEVICE FOR VOLUMETRIC IMAGING OF A THREE-DIMENSIONAL NUCLEIC ACID-CONTAINING MATRIX
|
US11718858B2
(en)
|
2015-11-11 |
2023-08-08 |
Regents Of The University Of Minnesota |
Biocontainment/biocontrol system and methods
|
US11905521B2
(en)
|
2015-11-17 |
2024-02-20 |
The Chinese University Of Hong Kong |
Methods and systems for targeted gene manipulation
|
AU2016355178B9
(en)
|
2015-11-19 |
2019-05-30 |
Massachusetts Institute Of Technology |
Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
|
US11542466B2
(en)
|
2015-12-22 |
2023-01-03 |
North Carolina State University |
Methods and compositions for delivery of CRISPR based antimicrobials
|
AU2016380836A1
(en)
|
2015-12-30 |
2018-07-12 |
Avectas Limited |
Vector-free delivery of gene editing proteins and compositions to cells and tissues
|
SG11201805792PA
(en)
|
2016-01-11 |
2018-08-30 |
Univ Leland Stanford Junior |
Chimeric proteins and methods of regulating gene expression
|
CN108463229B
(zh)
|
2016-01-11 |
2023-10-17 |
斯坦福大学托管董事会 |
嵌合蛋白和免疫治疗方法
|
CN105624187A
(zh)
*
|
2016-02-17 |
2016-06-01 |
天津大学 |
酿酒酵母基因组定点突变的方法
|
US20190249172A1
(en)
|
2016-02-18 |
2019-08-15 |
The Regents Of The University Of California |
Methods and compositions for gene editing in stem cells
|
WO2017151444A1
(en)
|
2016-02-29 |
2017-09-08 |
Agilent Technologies, Inc. |
Methods and compositions for blocking off-target nucleic acids from cleavage by crispr proteins
|
JP2019515654A
(ja)
|
2016-03-16 |
2019-06-13 |
ザ ジェイ. デヴィッド グラッドストーン インスティテューツ |
肥満及び/又は糖尿病を処置するための方法及び組成物、並びに候補処置薬剤を識別するための方法及び組成物
|
AU2017238512B2
(en)
|
2016-03-23 |
2022-12-08 |
Dana-Farber Cancer Institute, Inc. |
Methods for enhancing the efficiency of gene editing
|
WO2017165826A1
(en)
|
2016-03-25 |
2017-09-28 |
Editas Medicine, Inc. |
Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
|
US11512311B2
(en)
|
2016-03-25 |
2022-11-29 |
Editas Medicine, Inc. |
Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency
|
EP4047092A1
(en)
|
2016-04-13 |
2022-08-24 |
Editas Medicine, Inc. |
Cas9 fusion molecules, gene editing systems, and methods of use thereof
|
US11286478B2
(en)
|
2016-04-19 |
2022-03-29 |
The Broad Institute, Inc. |
Cpf1 complexes with reduced indel activity
|
KR102670601B1
(ko)
|
2016-04-19 |
2024-05-29 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신규한 crispr 효소 및 시스템
|
CN116200465A
(zh)
|
2016-04-25 |
2023-06-02 |
哈佛学院董事及会员团体 |
用于原位分子检测的杂交链反应方法
|
KR20170123581A
(ko)
*
|
2016-04-28 |
2017-11-08 |
연세대학교 산학협력단 |
in vivo에서 RNA-가이드 뉴클레아제의 활성을 고처리량 방식으로 평가하는 방법
|
CA3022997C
(en)
|
2016-05-20 |
2023-07-18 |
Regeneron Pharmaceuticals, Inc. |
Methods for breaking immunological tolerance using multiple guide rnas
|
US10266851B2
(en)
|
2016-06-02 |
2019-04-23 |
Sigma-Aldrich Co. Llc |
Using programmable DNA binding proteins to enhance targeted genome modification
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
WO2017223538A1
(en)
|
2016-06-24 |
2017-12-28 |
The Regents Of The University Of Colorado, A Body Corporate |
Methods for generating barcoded combinatorial libraries
|
WO2018022930A1
(en)
*
|
2016-07-27 |
2018-02-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Immolative cell-penetrating complexes for nucleic acid delivery
|
EP3491130B1
(en)
*
|
2016-07-28 |
2022-07-27 |
DSM IP Assets B.V. |
An assembly system for a eukaryotic cell
|
JP2019523009A
(ja)
|
2016-07-29 |
2019-08-22 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
C末端切断型フィブリリン−1の発現をもたらす変異を有するマウス
|
BR112019001887A2
(pt)
|
2016-08-02 |
2019-07-09 |
Editas Medicine Inc |
composições e métodos para o tratamento de doença associada a cep290
|
EP3494215A1
(en)
|
2016-08-03 |
2019-06-12 |
President and Fellows of Harvard College |
Adenosine nucleobase editors and uses thereof
|
JP7201153B2
(ja)
|
2016-08-09 |
2023-01-10 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
プログラム可能cas9-リコンビナーゼ融合タンパク質およびその使用
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
CA3035534A1
(en)
*
|
2016-09-07 |
2018-03-15 |
Sangamo Therapeutics, Inc. |
Modulation of liver genes
|
US20190225974A1
(en)
|
2016-09-23 |
2019-07-25 |
BASF Agricultural Solutions Seed US LLC |
Targeted genome optimization in plants
|
GB2569733B
(en)
|
2016-09-30 |
2022-09-14 |
Univ California |
RNA-guided nucleic acid modifying enzymes and methods of use thereof
|
US10669539B2
(en)
|
2016-10-06 |
2020-06-02 |
Pioneer Biolabs, Llc |
Methods and compositions for generating CRISPR guide RNA libraries
|
WO2018071868A1
(en)
|
2016-10-14 |
2018-04-19 |
President And Fellows Of Harvard College |
Aav delivery of nucleobase editors
|
US20200172899A1
(en)
|
2016-10-14 |
2020-06-04 |
The General Hospital Corporation |
Epigenetically Regulated Site-Specific Nucleases
|
CN110520530A
(zh)
|
2016-10-18 |
2019-11-29 |
明尼苏达大学董事会 |
肿瘤浸润性淋巴细胞和治疗方法
|
EP3541408A4
(en)
|
2016-11-15 |
2020-06-24 |
The Schepens Eye Research Institute, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS
|
JP2020502124A
(ja)
|
2016-12-14 |
2020-01-23 |
リガンダル インコーポレイテッド |
核酸および/またはタンパク質ペイロード送達のための組成物および方法
|
ES2924063T3
(es)
|
2016-12-22 |
2022-10-04 |
Avectas Ltd |
Liberación intracelular sin vector mediante permeabilización reversible
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
CN110520163A
(zh)
|
2017-01-05 |
2019-11-29 |
新泽西鲁特格斯州立大学 |
独立于dna双链断裂的靶向基因编辑平台及其用途
|
RU2021133626A
(ru)
|
2017-01-23 |
2022-01-31 |
Регенерон Фармасьютикалз, Инк. |
Варианты hsd17b13 и их применения
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
CA3053006C
(en)
|
2017-02-08 |
2023-09-05 |
Dana-Farber Cancer Institute, Inc. |
Regulating chimeric antigen receptors
|
WO2018165504A1
(en)
|
2017-03-09 |
2018-09-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
WO2018165629A1
(en)
|
2017-03-10 |
2018-09-13 |
President And Fellows Of Harvard College |
Cytosine to guanine base editor
|
EP3596217A1
(en)
|
2017-03-14 |
2020-01-22 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
IL269458B2
(en)
|
2017-03-23 |
2024-02-01 |
Harvard College |
Nucleic base editors that include nucleic acid programmable DNA binding proteins
|
WO2018191520A1
(en)
|
2017-04-12 |
2018-10-18 |
The Broad Institute, Inc. |
Respiratory and sweat gland ionocytes
|
WO2018195129A1
(en)
|
2017-04-17 |
2018-10-25 |
University Of Maryland, College Park |
Embryonic cell cultures and methods of using the same
|
BR112019021719A2
(pt)
|
2017-04-21 |
2020-06-16 |
The General Hospital Corporation |
Variantes de cpf1 (cas12a) com especificidade para pam alterada
|
US20200384115A1
(en)
|
2017-04-21 |
2020-12-10 |
The Broad Institute , Inc. |
Targeted delivery to beta cells
|
WO2018201086A1
(en)
|
2017-04-28 |
2018-11-01 |
Editas Medicine, Inc. |
Methods and systems for analyzing guide rna molecules
|
WO2018204777A2
(en)
|
2017-05-05 |
2018-11-08 |
The Broad Institute, Inc. |
Methods for identification and modification of lncrna associated with target genotypes and phenotypes
|
EP3622070A2
(en)
|
2017-05-10 |
2020-03-18 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease systems and methods
|
US11834665B2
(en)
|
2017-05-10 |
2023-12-05 |
Regents Of The University Of Minnesota |
Programmable transcription factors and methods
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
EP3630198A4
(en)
|
2017-05-25 |
2021-04-21 |
The General Hospital Corporation |
USE OF CLIVED DESAMINASES TO LIMIT UNWANTED OUT-OF-TARGET DESAMINATION FROM BASE EDITING
|
CN110719956A
(zh)
|
2017-06-06 |
2020-01-21 |
齐默尔根公司 |
用于改良真菌菌株的高通量基因组工程改造平台
|
ES2875579T3
(es)
|
2017-06-06 |
2021-11-10 |
Zymergen Inc |
Plataforma de ingeniería genómica de HTP para mejorar Escherichia coli
|
WO2018225807A1
(ja)
*
|
2017-06-07 |
2018-12-13 |
国立大学法人東京大学 |
顆粒状角膜変性症に対する遺伝子治療薬
|
WO2018227114A1
(en)
|
2017-06-09 |
2018-12-13 |
Editas Medicine, Inc. |
Engineered cas9 nucleases
|
EP3638317A4
(en)
|
2017-06-15 |
2021-03-17 |
The Regents of The University of California |
TARGETED NONVIRAL DNA INSERTIONS
|
US10011849B1
(en)
|
2017-06-23 |
2018-07-03 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
US9982279B1
(en)
|
2017-06-23 |
2018-05-29 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
JP2020530307A
(ja)
|
2017-06-30 |
2020-10-22 |
インティマ・バイオサイエンス,インコーポレーテッド |
遺伝子治療のためのアデノ随伴ウイルスベクター
|
WO2019014564A1
(en)
|
2017-07-14 |
2019-01-17 |
Editas Medicine, Inc. |
SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES
|
US11732274B2
(en)
|
2017-07-28 |
2023-08-22 |
President And Fellows Of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
|
KR20200032117A
(ko)
|
2017-07-31 |
2020-03-25 |
리제너론 파마슈티칼스 인코포레이티드 |
생체 내에서 외인성 공여체 핵산과의 CRISPR/Cas-유도된 재조합의 평가
|
MX2020001177A
(es)
|
2017-07-31 |
2020-09-25 |
Regeneron Pharma |
Animales no humanos reporteros de crispr y usos de los mismos.
|
US11130999B2
(en)
|
2017-07-31 |
2021-09-28 |
Regeneron Pharmaceuticals, Inc. |
Cas-ready mouse embryonic stem cells and mice and uses thereof
|
WO2019139645A2
(en)
|
2017-08-30 |
2019-07-18 |
President And Fellows Of Harvard College |
High efficiency base editors comprising gam
|
DK3688162T3
(da)
|
2017-09-29 |
2024-05-13 |
Intellia Therapeutics Inc |
Formuleringer
|
JP2020537541A
(ja)
|
2017-09-29 |
2020-12-24 |
インテリア セラピューティクス,インコーポレーテッド |
脂質ナノ粒子を用いるインビトロでのmrnaの送達方法
|
CN111417728A
(zh)
|
2017-09-29 |
2020-07-14 |
因特利亚治疗公司 |
用于ttr基因编辑及治疗attr淀粉样变性的组合物及方法
|
AR113154A1
(es)
|
2017-09-29 |
2020-01-29 |
Intellia Therapeutics Inc |
Polinucleótidos, composiciones y métodos para edición del genoma
|
ES2962277T3
(es)
|
2017-09-29 |
2024-03-18 |
Regeneron Pharma |
Roedores que comprenden un locus Ttr humanizado y métodos de uso
|
CN111757937A
(zh)
|
2017-10-16 |
2020-10-09 |
布罗德研究所股份有限公司 |
腺苷碱基编辑器的用途
|
IL274179B2
(en)
|
2017-10-27 |
2024-02-01 |
Univ California |
Targeted replacement of endogenous T cell receptors
|
WO2019099560A1
(en)
|
2017-11-14 |
2019-05-23 |
The Schepens Eye Research Institute, Inc. |
Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
|
BR112020014168A2
(pt)
|
2018-01-12 |
2020-12-08 |
Basf Se |
Proteína, ácido nucleico isolado, gene recombinante, vetor, célula hospedeira, planta, parte de planta ou semente de trigo, métodos para produzir, produto de trigo, farinha, farelo integral, amido, grânulos de amido ou farelo de trigo e métodos para identificar e/ou selecionar uma planta de trigo
|
WO2019147743A1
(en)
|
2018-01-26 |
2019-08-01 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
CA3089331A1
(en)
|
2018-03-19 |
2019-09-26 |
Regeneron Pharmaceuticals, Inc. |
Transcription modulation in animals using crispr/cas systems
|
GB2587970B
(en)
|
2018-04-19 |
2023-02-08 |
Univ California |
Compositions and methods for gene editing
|
GB2589246A
(en)
|
2018-05-16 |
2021-05-26 |
Synthego Corp |
Methods and systems for guide RNA design and use
|
US20210261901A1
(en)
|
2018-06-01 |
2021-08-26 |
Avectas Limited |
Cell engineering platform
|
JP2021530212A
(ja)
|
2018-07-13 |
2021-11-11 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California |
レトロトランスポゾンベースの送達媒体及びその使用方法
|
WO2020028327A1
(en)
|
2018-07-31 |
2020-02-06 |
Intellia Therapeutics, Inc. |
Compositions and methods for hydroxyacid oxidase 1 ( hao1) gene editing for treating primary hyperoxaluria type 1 (ph1)
|
KR20210053898A
(ko)
|
2018-07-31 |
2021-05-12 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신규 crispr 효소 및 시스템
|
CN110678553B
(zh)
*
|
2018-08-21 |
2023-08-11 |
中国医学科学院血液病医院(中国医学科学院血液学研究所) |
在哺乳动物干细胞中进行基因组编辑的方法
|
BR112021005718A2
(pt)
|
2018-09-28 |
2021-06-22 |
Intellia Therapeutics, Inc. |
composições e métodos para edição de genes de lactato desidrogenase (ldha)
|
WO2020072248A1
(en)
|
2018-10-01 |
2020-04-09 |
North Carolina State University |
Recombinant type i crispr-cas system
|
EP3867379A1
(en)
|
2018-10-16 |
2021-08-25 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunotherapy
|
US11407995B1
(en)
|
2018-10-26 |
2022-08-09 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
WO2020092704A1
(en)
|
2018-10-31 |
2020-05-07 |
Zymergen Inc. |
Multiplexed deterministic assembly of dna libraries
|
EP3874048A1
(en)
*
|
2018-11-01 |
2021-09-08 |
Keygene N.V. |
Dual guide rna for crispr/cas genome editing in plants cells
|
US11434477B1
(en)
|
2018-11-02 |
2022-09-06 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
KR20200071198A
(ko)
|
2018-12-10 |
2020-06-19 |
네오이뮨텍, 인코퍼레이티드 |
Nrf2 발현 조절 기반 T 세포 항암면역치료법
|
KR20210104068A
(ko)
|
2018-12-14 |
2021-08-24 |
파이어니어 하이 부렛드 인터내쇼날 인코포레이팃드 |
게놈 편집을 위한 신규한 crispr-cas 시스템
|
KR20210105914A
(ko)
|
2018-12-20 |
2021-08-27 |
리제너론 파마슈티칼스 인코포레이티드 |
뉴클레아제-매개 반복부 팽창
|
EP3911746A1
(en)
|
2019-01-14 |
2021-11-24 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and kits for generating and selecting a variant of a binding protein with increased binding affinity and/or specificity
|
EP3921417A4
(en)
|
2019-02-04 |
2022-11-09 |
The General Hospital Corporation |
ADENINE DNA BASE EDITOR VARIANTS WITH REDUCED OFF-TARGET RNA EDITING
|
WO2020163856A1
(en)
|
2019-02-10 |
2020-08-13 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Modified mitochondrion and methods of use thereof
|
EP4219700A1
(en)
|
2019-03-07 |
2023-08-02 |
The Regents of the University of California |
Crispr-cas effector polypeptides and methods of use thereof
|
US11053515B2
(en)
|
2019-03-08 |
2021-07-06 |
Zymergen Inc. |
Pooled genome editing in microbes
|
CA3129871A1
(en)
|
2019-03-08 |
2020-09-17 |
Zymergen Inc. |
Iterative genome editing in microbes
|
ES2969026T3
(es)
|
2019-03-18 |
2024-05-16 |
Regeneron Pharma |
Plataforma de detección de abandonos CRISPR/CAS para revelar vulnerabilidades genéticas asociadas con la agregación de tau
|
CN113631700A
(zh)
|
2019-03-18 |
2021-11-09 |
瑞泽恩制药公司 |
用于鉴定tau接种或聚集的基因修饰因子的CRISPR/Cas筛选平台
|
SG11202109882VA
(en)
|
2019-03-19 |
2021-10-28 |
Broad Inst Inc |
Methods and compositions for editing nucleotide sequences
|
AU2020248337A1
(en)
|
2019-03-28 |
2021-11-04 |
Intellia Therapeutics, Inc. |
Compositions and methods for ttr gene editing and treating ATTR amyloidosis comprising a corticosteroid or use thereof
|
CN113993994A
(zh)
|
2019-03-28 |
2022-01-28 |
因特利亚治疗公司 |
用于多肽表达的多核苷酸、组合物和方法
|
WO2020198697A1
(en)
|
2019-03-28 |
2020-10-01 |
Intellia Therapeutics, Inc. |
Compositions and methods comprising a ttr guide rna and a polynucleotide encoding an rna-guided dna binding agent
|
AU2020256225A1
(en)
|
2019-04-03 |
2021-09-02 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
|
CA3133360A1
(en)
|
2019-04-04 |
2020-10-08 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized coagulation factor 12 locus
|
CN113795588A
(zh)
|
2019-04-04 |
2021-12-14 |
瑞泽恩制药公司 |
用于在靶向性载体中无瘢痕引入靶向修饰的方法
|
AU2020286382A1
(en)
|
2019-06-04 |
2021-11-04 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized TTR locus with a beta-slip mutation and methods of use
|
KR20220017939A
(ko)
|
2019-06-07 |
2022-02-14 |
리제너론 파마슈티칼스 인코포레이티드 |
인간화 알부민 좌위를 포함하는 비-인간 동물
|
US11845957B2
(en)
|
2019-06-14 |
2023-12-19 |
Regeneron Pharmaceuticals, Inc. |
Models of tauopathy
|
EP4022057A1
(en)
|
2019-08-27 |
2022-07-06 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of disorders associated with repetitive dna
|
EP4028063A1
(en)
|
2019-09-13 |
2022-07-20 |
Regeneron Pharmaceuticals, Inc. |
Transcription modulation in animals using crispr/cas systems delivered by lipid nanoparticles
|
US20230025039A1
(en)
|
2019-09-20 |
2023-01-26 |
The Broad Institute, Inc. |
Novel type vi crispr enzymes and systems
|
BR112022008861A2
(pt)
|
2019-11-08 |
2022-08-23 |
Regeneron Pharma |
Construto de ácido nucleico, vetor, nanopartícula lipídica, célula, composição para uso na expressão de retinosquisina, método para integrar uma sequência de codificação, e, método para modificar um gene rs1
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
EP4064830A1
(en)
|
2019-11-29 |
2022-10-05 |
Basf Se |
Increasing resistance against fungal infections in plants
|
EP4077699A1
(en)
|
2019-12-19 |
2022-10-26 |
Basf Se |
Increasing space-time-yield, carbon-conversion-efficiency and carbon substrate flexibility in the production of fine chemicals
|
CN115135762A
(zh)
|
2019-12-20 |
2022-09-30 |
巴斯夫欧洲公司 |
降低萜烯的毒性和增加微生物的生产潜力
|
US11060141B1
(en)
|
2019-12-23 |
2021-07-13 |
Stilla Technologies |
Multiplex drop-off digital polymerase chain reaction methods
|
CN115485385A
(zh)
|
2020-03-04 |
2022-12-16 |
瑞泽恩制药公司 |
用于使肿瘤细胞对免疫疗法敏感的方法和组合物
|
EP4125348A1
(en)
|
2020-03-23 |
2023-02-08 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
|
US20210290757A1
(en)
|
2020-03-23 |
2021-09-23 |
Avectas Limited |
Engineering of dendritic cells for generation of vaccines against sars-cov-2
|
US20210319851A1
(en)
|
2020-04-03 |
2021-10-14 |
Creyon Bio, Inc. |
Oligonucleotide-based machine learning
|
WO2021204877A2
(en)
|
2020-04-08 |
2021-10-14 |
Astrazeneca Ab |
Compositions and methods for improved site-specific modification
|
KR20230017783A
(ko)
|
2020-04-28 |
2023-02-06 |
인텔리아 테라퓨틱스, 인크. |
시험관내 세포 전달 방법
|
JP2023525304A
(ja)
|
2020-05-08 |
2023-06-15 |
ザ ブロード インスティテュート,インコーポレーテッド |
標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物
|
US20230235315A1
(en)
|
2020-07-10 |
2023-07-27 |
Horizon Discovery Limited |
Method for producing genetically modified cells
|
TW202218686A
(zh)
|
2020-09-09 |
2022-05-16 |
美商維泰克斯製藥公司 |
用於治療杜興氏肌肉失養症(duchenne muscular dystrophy)之組合物及方法
|
US10947552B1
(en)
|
2020-09-30 |
2021-03-16 |
Alpine Roads, Inc. |
Recombinant fusion proteins for producing milk proteins in plants
|
US10894812B1
(en)
|
2020-09-30 |
2021-01-19 |
Alpine Roads, Inc. |
Recombinant milk proteins
|
EP4222167A1
(en)
|
2020-09-30 |
2023-08-09 |
Nobell Foods, Inc. |
Recombinant milk proteins and food compositions comprising the same
|
CA3196116A1
(en)
|
2020-10-21 |
2022-04-28 |
Omar Abudayyeh |
Systems, methods, and compositions for site-specific genetic engineering using programmable addition via site-specific targeting elements (paste)
|
EP4240854A1
(en)
|
2020-11-06 |
2023-09-13 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of dm1 with slucas9 and sacas9
|
WO2022120022A1
(en)
|
2020-12-02 |
2022-06-09 |
Regeneron Pharmaceuticals, Inc. |
Crispr sam biosensor cell lines and methods of use thereof
|
IL303505A
(en)
|
2020-12-11 |
2023-08-01 |
Intellia Therapeutics Inc |
Preparations and methods for reducing MHC CLASS II in the cell
|
EP4267724A2
(en)
|
2020-12-23 |
2023-11-01 |
Intellia Therapeutics, Inc. |
Compositions and methods for reducing hla-a in a cell
|
EP4267723A1
(en)
|
2020-12-23 |
2023-11-01 |
Intellia Therapeutics, Inc. |
Compositions and methods for genetically modifying ciita in a cell
|
EP4274893A1
(en)
|
2021-01-05 |
2023-11-15 |
Horizon Discovery Limited |
Method for producing genetically modified cells
|
WO2022162646A1
(en)
|
2021-02-01 |
2022-08-04 |
Avectas Limited |
Delivery platform
|
WO2022170172A1
(en)
|
2021-02-08 |
2022-08-11 |
Intellia Therapeutics, Inc. |
Natural killer cell receptor 2b4 compositions and methods for immunotherapy
|
EP4288089A2
(en)
|
2021-02-08 |
2023-12-13 |
Intellia Therapeutics, Inc. |
T-cell immunoglobulin and mucin domain 3 (tim3) compositions and methods for immunotherapy
|
EP4288088A2
(en)
|
2021-02-08 |
2023-12-13 |
Intellia Therapeutics, Inc. |
Lymphocyte activation gene 3 (lag3) compositions and methods for immunotherapy
|
WO2022182959A1
(en)
|
2021-02-26 |
2022-09-01 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/slucas9
|
WO2022182957A1
(en)
|
2021-02-26 |
2022-09-01 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/sacas9
|
WO2022216857A1
(en)
*
|
2021-04-07 |
2022-10-13 |
Century Therapeutics, Inc. |
Gene transfer vectors and methods of engineering cells
|
EP4320234A2
(en)
|
2021-04-07 |
2024-02-14 |
Astrazeneca AB |
Compositions and methods for site-specific modification
|
IL307741A
(en)
|
2021-04-17 |
2023-12-01 |
Intellia Therapeutics Inc |
Lipid nanoparticle compositions
|
AU2022258733A1
(en)
|
2021-04-17 |
2023-11-30 |
Intellia Therapeutics, Inc. |
Inhibitors of dna-dependent protein kinase and compositions and uses thereof
|
CR20230536A
(es)
|
2021-04-17 |
2024-03-08 |
Intellia Therapeutics Inc |
Composiciones de nanopartículas lipídicas
|
WO2022229851A1
(en)
|
2021-04-26 |
2022-11-03 |
Crispr Therapeutics Ag |
Compositions and methods for using slucas9 scaffold sequences
|
WO2022234519A1
(en)
|
2021-05-05 |
2022-11-10 |
Crispr Therapeutics Ag |
Compositions and methods for using sacas9 scaffold sequences
|
WO2022240846A1
(en)
|
2021-05-10 |
2022-11-17 |
Sqz Biotechnologies Company |
Methods for delivering genome editing molecules to the nucleus or cytosol of a cell and uses thereof
|
WO2022251644A1
(en)
|
2021-05-28 |
2022-12-01 |
Lyell Immunopharma, Inc. |
Nr4a3-deficient immune cells and uses thereof
|
JP2024520676A
(ja)
|
2021-06-02 |
2024-05-24 |
ライエル・イミュノファーマ・インコーポレイテッド |
Nr4a3欠損免疫細胞及びその使用
|
WO2023018637A1
(en)
|
2021-08-09 |
2023-02-16 |
Vertex Pharmaceuticals Incorporated |
Gene editing of regulatory elements
|
CN117940153A
(zh)
|
2021-08-24 |
2024-04-26 |
因特利亚治疗公司 |
用于基于细胞的疗法的程序性细胞死亡蛋白1(pd1)组合物和方法
|
WO2023039444A2
(en)
|
2021-09-08 |
2023-03-16 |
Vertex Pharmaceuticals Incorporated |
Precise excisions of portions of exon 51 for treatment of duchenne muscular dystrophy
|
WO2023039586A1
(en)
|
2021-09-10 |
2023-03-16 |
Agilent Technologies, Inc. |
Guide rnas with chemical modification for prime editing
|
CN118119707A
(zh)
|
2021-09-30 |
2024-05-31 |
阿斯利康(瑞典)有限公司 |
抑制剂增加CRISPR/Cas插入效率的用途
|
CN118119702A
(zh)
|
2021-10-14 |
2024-05-31 |
隆萨销售股份有限公司 |
用于细胞外囊泡产生的经修饰的生产者细胞
|
WO2023077053A2
(en)
|
2021-10-28 |
2023-05-04 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-related methods and compositions for knocking out c5
|
WO2023077148A1
(en)
|
2021-11-01 |
2023-05-04 |
Tome Biosciences, Inc. |
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
|
WO2023081200A2
(en)
|
2021-11-03 |
2023-05-11 |
Intellia Therapeutics, Inc. |
Cd38 compositions and methods for immunotherapy
|
WO2023081756A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
AU2022382975A1
(en)
|
2021-11-03 |
2024-05-02 |
Intellia Therapeutics, Inc. |
Polynucleotides, compositions, and methods for genome editing
|
AU2022408167A1
(en)
|
2021-12-08 |
2024-06-06 |
Regeneron Pharmaceuticals, Inc. |
Mutant myocilin disease model and uses thereof
|
US20230279442A1
(en)
|
2021-12-15 |
2023-09-07 |
Versitech Limited |
Engineered cas9-nucleases and method of use thereof
|
WO2023122764A1
(en)
|
2021-12-22 |
2023-06-29 |
Tome Biosciences, Inc. |
Co-delivery of a gene editor construct and a donor template
|
AU2022424002A1
(en)
|
2021-12-29 |
2024-06-13 |
Bristol-Myers Squibb Company |
Generation of landing pad cell lines
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2023150181A1
(en)
|
2022-02-01 |
2023-08-10 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
TW202332767A
(zh)
|
2022-02-02 |
2023-08-16 |
美商雷傑納榮製藥公司 |
用於治療龐貝氏症之抗TfR:GAA及抗CD63:GAA插入
|
WO2023172926A1
(en)
|
2022-03-08 |
2023-09-14 |
Vertex Pharmaceuticals Incorporated |
Precise excisions of portions of exons for treatment of duchenne muscular dystrophy
|
TW202345911A
(zh)
|
2022-03-08 |
2023-12-01 |
美商維泰克斯製藥公司 |
用於治療杜興氏肌肉失養症(duchenne muscular dystrophy)之部分外顯子44、50及53之精確切除
|
WO2023205744A1
(en)
|
2022-04-20 |
2023-10-26 |
Tome Biosciences, Inc. |
Programmable gene insertion compositions
|
WO2023212677A2
(en)
|
2022-04-29 |
2023-11-02 |
Regeneron Pharmaceuticals, Inc. |
Identification of tissue-specific extragenic safe harbors for gene therapy approaches
|
WO2023220603A1
(en)
|
2022-05-09 |
2023-11-16 |
Regeneron Pharmaceuticals, Inc. |
Vectors and methods for in vivo antibody production
|
WO2023225665A1
(en)
|
2022-05-19 |
2023-11-23 |
Lyell Immunopharma, Inc. |
Polynucleotides targeting nr4a3 and uses thereof
|
WO2023225670A2
(en)
|
2022-05-20 |
2023-11-23 |
Tome Biosciences, Inc. |
Ex vivo programmable gene insertion
|
WO2023235726A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr interference therapeutics for c9orf72 repeat expansion disease
|
WO2023235725A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr-based therapeutics for c9orf72 repeat expansion disease
|
WO2024020346A2
(en)
|
2022-07-18 |
2024-01-25 |
Renagade Therapeutics Management Inc. |
Gene editing components, systems, and methods of use
|
WO2024020352A1
(en)
|
2022-07-18 |
2024-01-25 |
Vertex Pharmaceuticals Incorporated |
Tandem guide rnas (tg-rnas) and their use in genome editing
|
WO2024020587A2
(en)
|
2022-07-22 |
2024-01-25 |
Tome Biosciences, Inc. |
Pleiopluripotent stem cell programmable gene insertion
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024031053A1
(en)
|
2022-08-05 |
2024-02-08 |
Regeneron Pharmaceuticals, Inc. |
Aggregation-resistant variants of tdp-43
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2024064952A1
(en)
|
2022-09-23 |
2024-03-28 |
Lyell Immunopharma, Inc. |
Methods for culturing nr4a-deficient cells overexpressing c-jun
|
WO2024064958A1
(en)
|
2022-09-23 |
2024-03-28 |
Lyell Immunopharma, Inc. |
Methods for culturing nr4a-deficient cells
|
WO2024073606A1
(en)
|
2022-09-28 |
2024-04-04 |
Regeneron Pharmaceuticals, Inc. |
Antibody resistant modified receptors to enhance cell-based therapies
|
WO2024077174A1
(en)
|
2022-10-05 |
2024-04-11 |
Lyell Immunopharma, Inc. |
Methods for culturing nr4a-deficient cells
|
WO2024098002A1
(en)
|
2022-11-04 |
2024-05-10 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
WO2024102434A1
(en)
|
2022-11-10 |
2024-05-16 |
Senda Biosciences, Inc. |
Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
|
WO2024107765A2
(en)
|
2022-11-14 |
2024-05-23 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|